ReviewCancer letters2017
MicroRNAs in gynecological cancers: Small molecules with big implications.
Review in Cancer letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Association of three micro-RNA gene polymorphisms with the risk of cervical cancer: a meta-analysis and systematic review.World journal of surgical oncology · 2021Pooled it
- Overview of miRNAs for the non-invasive diagnosis of endometriosis: evidence, challenges and strategies. A systematic review.Einstein (Sao Paulo, Brazil) · 2021Pooled it
- Integrating Metabolic and MicroRNA Profiling to the Diagnostics of Endometriosis: A Pilot Study.International journal of molecular sciences · 2026Article
- Mechanism of action of MiR-330-5p targeting ITGA5 in the regulation of proliferation, migration, and invasionof gastric cancer.BMC cancer · 2026Article
- Circulating microRNAs and endometriosis: a comprehensive analysis and validation of identified biomarkers in an Indian population.Reproduction & fertility · 2025Article
- Review
- mirTarCLASH: a comprehensive miRNA target database based on chimeric read-based experiments.Database : the journal of biological databases and curation · 2025Article
- Quercetin and microRNA Interplay in Apoptosis Regulation: A New Therapeutic Strategy for Cancer?Current medicinal chemistry · 2025Review
- ExplORRNet: An interactive web tool to explore stage-wise miRNA expression profiles and their interactions with mRNA and lncRNA in human breast and gynecological cancers.Non-coding RNA research · 2024Article
- Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms.Nutrients · 2024Review
- A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.Journal of ovarian research · 2022Review
- Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review.International journal of cancer · 2022Review
- Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer.Gynecologic oncology reports · 2022Article
- miR-335 Restrains the Aggressive Phenotypes of Ovarian Cancer Cells by Inhibiting COL11A1.Cancers · 2021Article
- miRNAs and lncRNAs: Potential Non-Invasive Biomarkers for Endometriosis.Biomedicines · 2021Review
- Article
- LncRNAInternational journal of molecular sciences · 2021Review
- MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study.Biomarker research · 2021Article
- MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer.Cellular & molecular biology letters · 2021Article
- Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Gynecological cancers (GCs) are often diagnosed at advanced stages, limiting the efficacy of available therapeutic options. Thus, there remains an urgent and unmet need for innovative research for the efficient clinical management of GC patients. Research over past several years has revealed the enormous promise of miRNAs. These small non-coding RNAs can aid in the diagnosis, prognosis and therapy of all major GCs, viz., ovarian cancers, cervical cancers and endometrial cancers. Mechanistic details of the miRNAs-mediated regulation of multiple biological functions are under constant investigation, and a number of miRNAs are now believed to influence growth, proliferation, invasion, metastasis, chemoresistance and the relapse of different GCs. Modulation of tumor microenvironment by miRNAs can possibly explain some of their reported biological effects. miRNA signatures have been proposed as biomarkers for the early detection of GCs, even the various subtypes of individual GCs. miRNA signatures are also being pursued as predictors of response to therapies. This review catalogs the knowledge gained from collective studies, so as to assess the progress made so far. It is time to ponder over the knowledge gained, so that more meaningful pre-clinical and translational studies can be designed to better realize the potential that miRNAs have to offer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.